US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Articles published by HOOKIPA Pharma Inc.

< Previous 1 2 Next >
News headline image
HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK LSE
News headline image
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK LSE
News headline image
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK LSE
News headline image
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK LSE
News headline image
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK LSE
News headline image
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK LSE
News headline image
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Announces Board of Directors Changes
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers ARVN HOOK
News headline image
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
News headline image
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Tickers HOOK
< Previous 1 2 Next >